Literature DB >> 33867725

Markers of Thrombin Generation and Inflammation in Patients with Paroxysmal Nocturnal Hemoglobinuria.

Rishi Dhawan1,2, Jasmina Ahluwalia3, Pankaj Malhotra2, Manoranjan Mahapatra1, Neelam Varma3, Subhash Varma2.   

Abstract

Paroxysmal nocturnal hemoglobinuria (PNH) presents with intravascular hemolysis, bone marrow failure and thrombosis. Various studies have reported geographic and ethnic variation in prevalence of thrombosis in PNH. There is limited data on thrombosis in PNH from the Indian subcontinent. In this study we describe disease burden and risk factors for thrombosis in 18 Indian PNH patients. We studied markers of thrombin generation (Thrombin-antithrombin complexes; TAT and D-Dimer), endothelium and platelet activation (soluble P-selectin) and inflammation (interleukin-6; IL-6) in PNH patients and compared their levels with healthy controls. Thrombosis was identified in 17% of PNH patients. TAT, sP-selectin and D-Dimer levels were significantly elevated in PNH patients (TAT: 5.06 ± 1.08 ng/ml; sP-selectin: 80.57 ± 19.5 ng/ml; D-Dimer mean: 936 ng/ml 95% CI 559, 1310) compared to control population (TAT: 3.39 ± 0.769 ng/ml P = 0.016; sP-selectin: 44.67 ± 5.17 ng/ml P = 0.002). Using Youden's J statistic, the cut-off values for TAT and sP-selectin in our cohort of PNH patients were 2.90 ng/ml and 58.41 ng/ml respectively. TAT, sP-selectin and D-Dimer levels were elevated beyond the cut-off values in PNH patients with thrombosis compared to those without thrombosis. A positive correlation was noted between TAT, sP-selectin and D-Dimer levels. Increased TAT, sP-selectin, and D-Dimer levels may indicate impending thrombosis in PNH. © Indian Society of Hematology and Blood Transfusion 2019.

Entities:  

Keywords:  D-Dimer; Inflammation; P-selectin; Paroxysmal nocturnal hemoglobinuria; Thrombin–antithrombin complexes; Thrombosis

Year:  2019        PMID: 33867725      PMCID: PMC8012422          DOI: 10.1007/s12288-019-01239-x

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN: 0971-4502            Impact factor:   0.900


  24 in total

1.  Paroxysmal nocturnal haemoglobinuria in Indians.

Authors:  P R Koduri; S Gowrishankar
Journal:  Acta Haematol       Date:  1992       Impact factor: 2.195

2.  Characteristics of paroxysmal nocturnal hemoglobinuria in China. Clinical analysis of 476 cases.

Authors:  X F Le; T Y Yang; X Y Yang; X M Wang
Journal:  Chin Med J (Engl)       Date:  1990-11       Impact factor: 2.628

3.  High incidence of thrombosis in African-American and Latin-American patients with Paroxysmal Nocturnal Haemoglobinuria.

Authors:  David J Araten; Howard T Thaler; Lucio Luzzatto
Journal:  Thromb Haemost       Date:  2005-01       Impact factor: 5.249

4.  Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors. French Society of Haematology.

Authors:  G Socié; J Y Mary; A de Gramont; B Rio; M Leporrier; C Rose; P Heudier; H Rochant; J Y Cahn; E Gluckman
Journal:  Lancet       Date:  1996-08-31       Impact factor: 79.321

5.  Prednisolone dose-dependently influences inflammation and coagulation during human endotoxemia.

Authors:  Martijn D de Kruif; Lucienne C Lemaire; Ida A Giebelen; Marieke A D van Zoelen; Jennie M Pater; Petra S van den Pangaart; Angelique P Groot; Alex F de Vos; Peter J Elliott; Joost C M Meijers; Marcel Levi; Tom van der Poll
Journal:  J Immunol       Date:  2007-02-01       Impact factor: 5.422

6.  Evaluation of hemostasis and endothelial function in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab.

Authors:  Dominique Helley; Régis Peffault de Latour; Raphaël Porcher; Celso Arrais Rodrigues; Isabelle Galy-Fauroux; Jeanne Matheron; Arnaud Duval; Jean-François Schved; Anne-Marie Fischer; Gérard Socié
Journal:  Haematologica       Date:  2010-01-15       Impact factor: 9.941

7.  Natural history of paroxysmal nocturnal haemoglobinuria using modern diagnostic assays.

Authors:  Victor M Moyo; Galina L Mukhina; Elizabeth S Garrett; Robert A Brodsky
Journal:  Br J Haematol       Date:  2004-07       Impact factor: 6.998

8.  Incidence of aplastic anemia: the relevance of diagnostic criteria. By the International Agranulocytosis and Aplastic Anemia Study.

Authors: 
Journal:  Blood       Date:  1987-12       Impact factor: 22.113

9.  Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria.

Authors:  Peter Hillmen; Petra Muus; Ulrich Dührsen; Antonio M Risitano; Jörg Schubert; Lucio Luzzatto; Hubert Schrezenmeier; Jeffrey Szer; Robert A Brodsky; Anita Hill; Gerard Socié; Monica Bessler; Scott A Rollins; Leonard Bell; Russell P Rother; Neal S Young
Journal:  Blood       Date:  2007-08-16       Impact factor: 22.113

10.  Evaluation of danazol, cyclosporine, and prednisolone as single agent or in combination for paroxysmal nocturnal hemoglobinuria.

Authors:  Kanjaksha Ghosh; Manisha Madkaikar; Maya Gupta; Farah Jijina
Journal:  Turk J Haematol       Date:  2013-12-05       Impact factor: 1.831

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.